Cellular and Molecular Biology
E-ISSN : 1165-158X / P-ISSN : 0145-5680
www.cellmolbiol.org

Original Research

Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo

Xuewen Xiang, Fang Wang, Ni Zhao, Zhao Zhou*

Department of Obstetrics, Jiaozhou Central Hospital, Qingdao 266300, China

*Correspondence to: zhouzhaoiio@163.com

Received September 4, 2020; Accepted November 28, 2020; Published December 31, 2020

Doi: http://dx.doi.org/10.14715/cmb/2020.66.8.2

Abstract: This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines. This randomized multi-center clinical trial was performed with random division into three groups of 393 pregnant women with mild to moderate chronic hypertension. From the beginning of the pregnancy to the end of the puerperium, the low dosage aspirin group (n = 129), the labetalol group (n = 127), and the drug-free or control group (n = 126) reported both mother and child results. Major variations in the presence of severely motherly hypertension, pre-eclampsia, renal failure, ECG shifts, and cardiovascular rupture between treatment groups (low doses of aspirin and labetalol) and control groups were noted. Repeated placenta and blood pressure control hospitalizations. (P<0.001) in the control group more often (untreated). The new babies were more vulnerable to gestational age (SGA), neonatal hypotension, neonatal Hyperbilirubinemia, and ICU (p <0.001 in contrast with the low-dose aspirin and control groups). In the control group, the proportion of premature babies was considerably higher than in the treatment group (p<0,05). A mild to moderate persistent high blood pressure during pregnancy therapy helps minimize mother and child occurrence. The use of labetalol is correlated with a higher incidence of SGA, neonatal hypotension, and neonatal hyperbilirubinemia relative to low-dose aspirin or control group.

Key words: Pregnancy-induced hypertension; Labetalol; Low dose aspirin; Placebo; Metabolic changes.

Introduction

Pregnancy is distinguished from the start of pregnancy by apparent metabolic and hemodynamic changes. The essential improvements in hemodynamics include increasing heat production during the first quarter of pregnancy, increasing plasma volume due in the first 30 weeks of sodium retention and water retention, and lowering systemic vascular tension. Systemic Arteries (1). Systemic Arteries. About 25% decrease in the resistance to systemic vascular effects due to the increased development and decreased responsiveness of norepinephrine and Angiotensin of vasodilators such as nitrogen oxide and prostacyclin (1). Diastolic blood pressure began to decline after the seventh week of pregnancy and dropped by 10 mm Hg between 24 and 26 weeks, returning to normal in the third quarter (2, 3). Any modifications during pregnancy can occur. Hypertension (multiple studies have shown that hypertension affects 7-10% of pregnant women) (4, 5) is the most frequent in women's world complications and has higher mortality and maternal morbidity. Hypertension is also the world's second most significant cause of maternal mortality (14%), (6) and 192 people are estimated to be killed every day during pregnancy due to high blood circulation (7). Two pregnancies considered the leading causes of perinatal, maternal, and death are hypertense Preeclampsia and Eclampsia (5). The diseases affect 3% to 5% of pregnancies and cause every year in the world, 60,000 maternal deaths and 500,000 fetal mortality (8).

During pregnancy, hypertension is a condition in pregnant women with more than 140 mm Hg and more 90mmHg with systolic blood pressure (9-11). Hypertension, proteinuria, heart failure, and renal failure are the disorder's clinical signs in severe cases. Worse, the welfare of fetuses and children's women is also under assault. In China, hypertension linked to pregnancy is around 9.4% and 10.1% (12).

Approximately 1-5 percent of women born in different communities experience recurrent hypertension. Women with persistent high blood pressure are at greater risk of complications for their mothers and children. However, whether antihypertensive drugs may reduce this risk during pregnancy is not understood (13-15). Antihypertensive medication to reduce blood pressures did not impact gestational age (GAA) or the likelihood of low stature of pre-eclampsia in a recent systematic review and meta-analysis (16). In a recent clinical report, the possibility of extreme hypertension rises (adjusted odds ratio is 1.8) if blood pressure is not strictly controlled) (17). A recent four-year retrospective study found that mothers and children's complications increase following discontinuation of medicines used in mild to moderate chronic arterial hypertension (18). This study aimed to determine maternal and fetal results compared to any medication for women with mild to medium chronic high blood pressure treated with Antihypertensive Therapy (low-dose aspirin or labetalol).

Materials and Methods

In conjunction with individual hospitals' cardiology and pediatric departments, the randomized clinical trial has taken place from early August 2018 to the end of August 2019 in obstetrics and gynecology in university hospitals. The research procedure was reviewed by the University Hospital Ethics Committee and officially approved. Both study participants signed a consent form after thorough clarification of the study goals. The study consisted of females with mild to moderate chronic hypertension in the first trimester (6 to 10 weeks) and systemic blood pressure between 140 and 159 mmHg or diastolic blood pressure between 90 and 109 mmHg without medication and disease in the target organ. This begins with a full clinical examination and the necessary laboratory tests after a medical history (such as blood counts, kidney and liver function tests). Fundus, ECG, and ultrasound obstetric test. Women with multiple embryos, prior proteinuria, and other conditions such as diabetes and asthma) as well as fetal defects during pregnancy were removed from the research. A block diagram appears in Figure 1. They were using a simple random table for randomization after selection. In a 1:1:1 ratio patient was divided randomly into three groups.

Randomization

All patients were divided randomly into 3 groups. Group 1 included 129 patients who received low dose aspirin; group 2 included 127 patients who received labetalol, group 3 had 126 patients who received placebo.

In three women, the risk of pre-eclampsia has been decreased by the low-dose aspirin treatment of 12 to 36 weeks of pregnancy. According to previous BP readings, during the prenatal checkup, take a variety of blood pressure (BP) readings and frequently take blood pressure readings every 2 to 4 weeks. Drug therapy should target for BPB less than 100-105 mmHg and for SBP less than 160 mmHg. Change the dosage according to blood pressure levels if participants increase the side effects. In patients with high blood pressure who receive the full dose of particular antihypertensive medicines in the study, other antihypertensive medicines can be taken at any time. Regular prenatal and postnatal visits continue, and the obstetric outcomes of the participants are registered.



Figure 1. Flow diagram of randomization.

Outcome measures

Maternal outcome

High blood pressure (systolic blood pressure 160 mm Hg or diastolic blood pressure 110 mm Hg) and development of superimposed pre-eclampsia at all times during pregnancy (defined as proteinuria within 24 hours and protein content of 0.3 g or more). Urinogenic test every hour after 20 weeks of pregnancy), eclampsia (generalized seizures), renal insufficiency develops (defined by a rise in serum creatinine > 1.1 mg/dl), liver failures develop (defined as increase liver enzymes), normal value development, ECG (left ventricular raise and/or blood pressure pattern) change, pre-bling bleeding, and hypertension.

Fetal-neonatal outcome

The birth weight <10 percentile, is defined as smaller than gestational age (SGA). Percentage, premature delivery (delivery before 37 weeks), neonatal hypoglycemia (low plasma glucose levels 30 mg/dL within 24 hours after the birth), neonatal hyperbilirubinemia (High Serum bilirubin or more 2 mg/dL), intrauterine fetal demise (IUFD). Waitz et al. (19) calculated the average 10 percentile of birth weight based on average 24 hours after the birth).

Statistical analysis

To tabulate and analyses data collected, use Social Science Statistical Software Package (Chicago, Illinois, USA) 22 and use the Chi-square and Fisher test for analysis, if appropriate. Odds (OR) is the indicator of the exposure-to-calculated value relationship. Statistically important is a P value of less than 0.05, while a P value of less than 0.001 is of considerable high significance.

Results

In terms of age, delivery numbers and body mass index, and systolic and diastolic blood pressure at the registration date, there were no major variations in demographics in the three classes of pregnant women. The gestational age at the start of the trial, the length of chronic hypertension, and the history of obstetrical adverse effects ($p>0.05$), as shown in Table 1 and Figure 2.

There were substantial disparities in extreme maternal hypertension, pre-eclampsia, renal failure, and blood



Figure 2. Frequency and age distribution of low dose aspirin, labetalol and placebo for different age group.

Table 1. Maternal characteristics of low dose aspirin, labetalol and placebo for different age group.

	Low dose aspirin (n=129)	Labetalol group (n=127)	Placebo group (n=126)	Chi square test	P-value
Age (years): 19-29, 30-39	62 (48%) 67 (53%)	56 (44%) 71 (55%)	58 (46%) 68 (55%)	0.48	0.75
Parity: P 1-2, ≥3	54 (41.5%) 75 (58.5%)	52 (41.25%) 75 (58.75%)	50 (39.5%) 76 (60.5%)	0.14	0.95
BMI (Kg/m2): 17-24, 24.1-28.9, ≥29	63 (49%) 42 (33%) 24 (19%)	62 (49%) 40 (32%) 25 (21%)	59 (47%) 41 (33%) 27 (24%)	0.46	0.99
Systolic blood pressure at the time of registration (mmHg)	151.1±4.87	152.12 ±4.99	150.1±5.1	0.51	>0.05
Diastolic blood pressure at the time of registration: (mmHg)	99.1±4.67	97.25±4.51	99.2±3.99	0.43	>0.05
Weeks of pregnancy at registration:	9.01±2.01	9.0±2.01	8.41±2.01	0.39	>0.05
Hypertensive history (years)	2.42±2.12	2.9±2.01	4±2.04	0.35	>0.05
Complications of previous obstetrics results:	40 (29.9%)	39 (29.8%)	41 (31.9%)	0.78	>0.05

Table 2. Maternal outcome of low dose aspirin, labetalol and placebo for different parameters.

	Low dose aspirin (n=129)	Labetalol group (n=127)	Placebo group (n=126)	Chi square test	P-value
Severe hypertension	30 (23.2%)	28 (21.3%)	67 (53.1%)	46.08	<0.001
Preeclampsia (PE)	40 (30.5%)	38 (30%)	61 (48/1%)	15.10	<0.001
Renal impairment	27 (20.7%)	29 (22.5%)	68 (54.3%)	53.12	<0.001
Liver dysfunction	32 (25.5%)	30 (22.8%)	36 (29.5%)	2.1	<0.001
Changes in ECG	33 (26.5%)	32 (24%)	70 (56%)	42.81	<0.001
Placental abruption	8 (6.1%)	10 (7.5%)	30 (23.5%)	28.12	<0.001
Hospital admission	35 (26.8%)	22 (17.5%)	59 (46.9%)	35.12	<0.001
Venousthromboembolism	3 (2.4%)	3 (2.5%)	5 (3.7%)	0.61	0.69
Cesarean delivery	40 (29.9%)	38 (29.8%)	40 (31.2)	0.19	0.951
Maternal mortality	0	0	0	0	0

pressure changes between the treatment group (low-dose aspirin and labetalol) and the control group. In the control group ECG, placental rupture, and multiple hospitalizations (p <0.001) were more common (untreated). The frequency of liver failure, venous thromboembolism, and a cesarean section of various groups was not substantially different (p>0.05), as shown in Table 2 and Figure 3.

Neonates in the labetalol group have a greater probability of using ICU than low-dose aspirin and controls since it is pregnant, neonatal, and ICU (P <0.001). In the control group, the proportion of premature babies was considerably higher than in the treatment group (p<0,05). In the incident of IUFD, neonatal hypoglycemia, and mortality among different groups (p>0.05), there were no substantial differences, as shown in Table 3 and Figure 4.

Discussion

This research involved a substantial reduction in extreme maternal hypertension, pre-eclampsia, renal failure, ECG, placental rupture, and hospitalization with mild to moderate chronic hypertension. The results are presented here. Repeat. 29,842 mothers and children of women with recurrent hypertension have been released



Figure 3. Maternal outcomes of low dose aspirin, labetalol and placebo for different parameters.



Figure 4. Fetal and neonatal outcome of low dose aspirin, labetalol and placebo for different parameters

Table 3. Fetal and neonatal outcome of low dose aspirin, labetalol and placebo for different parameters.

	Low dose aspirin (n=129)	Labetalol group (n=127)	Placebo group (n=126)	Chi square test	P-value
SGA	27 (21.8%)	53 (42.4%)	25 (20.17%)	24.10	<0.001
Intrauterine fetal demis	3 (2.4%)	3 (2.5%)	5 (3.7%)	0.61	0.76
Prematurity	24 (18.3%)	34 (27%)	39 (30/9%)	6.99	0.03
Neonatal hypotension	7 (5%)	21 (16.3%)	3 (2.5%)	24.91	<0.001
Neonatal hypoglycemia	5 (3.7%)	6 (5%)	3 (2.5%)	2.01	0.51
Neonatal hyperbilirubinemia	19 (14.6%)	41 (32.5%)	16 (12.3%)	25.21	<0.001
Admission to NICU	19 (14.6%)	38 (30%)	20 (16%)	14.89	<0.001
Neonatal mortality	3 (2.5%)	10 (7.5%)	6 (5%)	4.53	0.15

from the hospital in a population-based retrospective cohort study relative to women to treat stroke, renal failure, pulmonary edema, extreme pre-eclampsia, and placental rupture. 150 women with mild to moderate pregnancy-related high blood pressure have also obtained a further prospective, randomized study of Molvi et al. (20). These women have been randomized for standard care, low-dose aspirin, and standard treatment or only Labetalol standard control in this community. Compared to the control team, all treatment groups showed a substantial decrease in the rate of severe hypertension and proteinuria. The low-dose aspirin was severe in 16.3% of women hospitalized with hypertension compared with just 4% of labetalol. 40.6% of females in the weakest control group (n=493) had severe high blood pressure (to 160/110 mm Hg), and 27.5% in the severe control group (n=488) were females in the CHIPS sample (21). The use of antihypertensive medicines for mild or moderate hypertension during pregnancy, as defined in a recent Cochrane report (22), can substantially reduce the risk of severe hypertension while having an uncertain effect for other clinically relevant results. While there have been fewer premature births, neonatal hypotension, neonatal hyperbilirubinemia, and hospitalizations in infants in the labetalol community were significantly higher in this research. "No A foreseeable analysis carried out in a future study 109 babies born to mothers with extreme pre-eclampsia, in which 55 were exposed to labetalol and 54 were exposed to non-exposure (checking), which is more regular with Neonatal Hypotension after moms are administered labetalol, irrespective of their dosing and path (23). As all subjects used low intake aspirin, there were no discrepancies in perinatal mortality (IUFD and newborn) between the treatment and control groups. A previous systematic study found that aspirin would decrease the risk of perinatal death and pre-eclampsia in women with historical risk factors (24, 25). The gestational ages of mothers with labetalol is shorter than those of moms with low or untreated aspirin in this study (41.25 percent, 20.7 percent, and 19.75 percent, respectively). In the third trimester of pregnancy, the investigation began to treat women. The birth weight of women treated with chronic hypertension was decreased for <18 weeks, according to postmortem reports. The results can be better for women with low aspirin doses (compared to labetalol), particularly in women with high blood pressure. The study was divided into four groups: pregnancy-induced hypertension (113 cases), pregnancies, and hypertension. 242 hypertensive patients were treated with nifedipine or labetalol throughout pregnancy (73 cases). Mild (77) pre-eclampsia; severe (31) and HELLP syndromes pre-eclampsia (21 cases). In females with labetalol Nifedipine treated (38.8 percent versus 15.5 percent; p <0.05), the intrauterine growth rate was higher but only in the subgroup of females with moderate pre-eclampsia and hypertension caused by pregnancy. Low-grade hypertension Labetalol can affect fetal growth and behavior (26). Numerous studies have shown that in severe hypertension, labetalol can regulate blood pressure faster. Higher prices are the only restricting factor compared to low-dose aspirin (27-30). The key benefits of this study are the nature of a research project, early participation of participants, high response rate, addition to the short-term effects of drugs on newborns. Administration of low-dose aspirin to pregnant women results in small to moderate benefits. Further studies are needed to evaluate this issue such as study on bacteriology, genetic, biochemical, pathology, nanobiotechnology cytotoxicity and apoptosis (31-42). The new test's unintended disadvantage is the failure to provide constant blood pressure reading during the second section.

Treatment during pregnancy with mild to moderate chronic high blood pressure may help minimize mothers' and children's incidence. The use of labetalol is correlated with a higher incidence of SGA, neonatal hypotension, and neonatal hyperbilirubinemia relative to low- dose aspirin or the control group.

References

1. Gongora MC, Wenger NK. Cardiovascular complications of pregnancy. Int J Mol Sci 2015; 16(10): 23905-23928.

2. Flack JM, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. Cardiol Clin 2002; 20(2): 303-319, vii.

3. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy 2012; 2012.

4. Ahmad A, Samuelsen S. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG: Int J Obstet Gynecol 2012; 119(12): 1521-1528.

5. Lindheimer M, Taler S, Cunningham F. ASH position article: hypertension in pregnancy. J Am Soc Hypertens 2010; 4: 68-78.

6. Say L, Chou D, Gemmill A et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014; 2(6): e323-e333.

7. Folic M, Folic N, Varjacic M, Jakovljevic M, Jankovic S. Antihypertensive drug therapy for hypertensive disorders in pregnancy. Acta Med Medianae 2008; 47(3): 65-72.

8. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009; 113(6): 1299-1306.

9. Hou Y, Yun L, Zhang L, Lin J, Xu R. A risk factor-based predictive model for new-onset hypertension during pregnancy in Chinese Han women. BMC Cardiovasc Disord 2020; 20: 1-10.
10. Kobashi G. Genetic and environmental factors associated with the development of hypertension in pregnancy. J Epidemiol 2006; 16(1): 1-8.
11. Rudman SS, Mustapic M, Kosec V, Pivac N, Rudman F, Muck-Seler D. Serotonin risk factors for the development of hypertension in pregnancy. Arch Gynecol Obstet 2015; 291(4): 779-785.
12. Shao Y, Yao Y, Chen Y et al. Efficacy of magnesium sulfate combined with labetalol for treatment of gestational hypertension and its effects on pregnancy outcome: a meta-analysis. J Shenyang Med College 2019; (4): 3.
13. Gilbert WM, Young AL, Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med 2007; 52(11): 1046-1051.
14. Seely EW, Ecker J. Clinical practice. Chronic hypertension in pregnancy. N Engl J Med Overseas Ed 2011; 365(5): 439-446.
15. Rezk M, Ellakwa H, Gamal A, Emara M. Maternal and fetal morbidity following discontinuation of antihypertensive drugs in mild to moderate chronic hypertension: A 4-year observational study. Pregnancy Hypertension: Int J Women's Cardiovasc Health 2016; 6(4): 291-294.
16. Vasapollo B, Novelli GP, Gagliardi G, Farsetti D, Valensise H. Pregnancy complications in chronic hypertensive patients are linked to pre-pregnancy maternal cardiac function and structure. Am J Obstet Gynecol 2020.
17. Magee L, Group CS, von Dadelszen P et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG: Int J Obstet Gynaecol 2016; 123(7): 1143-1151.
18. Rezk M, Ellakwa H, Gamal A, Emara M. Maternal and fetal morbidity following discontinuation of antihypertensive drugs in mild to moderate chronic hypertension: A 4-year observational study. Pregnancy Hypertens 2016; 6(4): 291-294.
19. Waitz M, Nusser S, Schmid MB, Dreyhaupt J, Reister F, Hummler H. Risk factors associated with intraventricular hemorrhage in preterm infants with≤ 28 weeks gestational age. Klinische Pädiatrie 2016; 228(05): 245-250.
20. Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012; 285(6): 1553-1562.
21. Magee LA, Rey E, Asztalos E et al. Management of non-severe pregnancy hypertension–A summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications. Pregnancy Hypertension 2019; 18: 156-162.
22. LeFevre N, Krumm E. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Am Family Physic 2019; 100(7): 403-405.
23. Heida KY, Zeeman GG, Van Veen TR, Hulzebos CV. Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early human development Jul 2012; 88(7): 503-507.
24. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101(6): 1319-1332.
25. Moore GS, Allshouse AA, Post AL, Galan HL, Heyborne KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. J Perinatol 2015; 35(5): 328-331.
26. Giannubilo SR, Bezzeccheri V, Cecchi S et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet 2012; 286(3): 637-642.
27. el-Qarmalawi AM, Morsy AH, al-Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet 1995; 49(2): 125-130.
28. Pentareddy MR, Shailendra D, Prasuna G, Subbaratnam Y, Naresh D, Katta R. Safety and efficacy of methyldopa and labetalol in controlling blood pressure in hypertensive disorders of pregnancy. Int J Basic Clinic Pharmacol 2017; 6(4): 942-947.
29. Kazemi E, Zargooshi J Kaboudi M, Heidari P, Kahrizi D, Mahaki B, Mohammadian Y, Khazaei H, Ahmed K. A genome-wide association study to identify candidate genes for erectile dysfunction. Brief Bioinform 2020; bbaa338, https://doi.org/10.1093/bib/bbaa338.
30. Maheshwari N, Wagh R, Sharma S, Mutalik M, Gupta M, Siddiqui W. Role of labetalol and methyldopa in newly diagnosed mild hypertension in pregnancy: a prospective drug comparative study in a rural tertiary care hospital in India. Int J Pharm Sci Res 2017; 8(1): 226.
31. Lin J, Wang Y, Wei X, Kong S, Liu Z, Liu J, Zhang F, Lin S, Ji B, Zhou Z, Guo Z. Controllable antibacterial and bacterially anti-adhesive surface fabricated by a bio-inspired beetle-like macromolecule. Int J Biol Macromol 2020. Doi: 10.1016/j.ijbiomac.2020.04.207.
32. Zhang J, Liu B. A review on the recent developments of sequence-based protein feature extraction methods. Curr Bioinform 2019;14(3):190-9. Doi: 10.2174/1574893614666181212102749.
33. Xu L, Jiang S, Zou Q. An in silico approach to identification, categorization and prediction of nucleic acid binding proteins. bioRxiv. 2020. Doi: 10.1093/bib/ bbaa171.
34. Zhu S, Wang X, Zheng Z, Zhao XE, Bai Y, Liu H. Synchronous measuring of triptolide changes in rat brain and blood and its application to a comparative pharmacokinetic study in normal and Alzheimer's disease rats. J Pharmaceutic Biomed Anal 2020;113263. Doi: 10.1016/j.jpba.2020.113263.
35. Zhu S, Zheng Z, Peng H, Sun J, Zhao XE, Liu H. Quadruplex stable isotope derivatization strategy for the determination of panaxadiol and panaxatriol in foodstuffs and medicinal materials using ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr A. 2020; 1616:460794. Doi: 10.1016/j.chroma.2019.460794.
36. Chen G, Li Y, Ren Z, Gu Y, Tang F, Mao J, Zhu J, Wang L, Li Y. Clinical Significance of MicroRNA-155-Regulated Autophagy and Apoptosis by Targeting Rictor/Fos in Gastric Cancer Progression. Nanosci Nanotechnol Lett 2020; 12(4):525-35.
37. Alkhudhayri AA, Wahab R, Siddiqui MA, Ahmad J. Selenium Nanoparticles Induce Cytotoxicity and Apoptosis in Human Breast Cancer (MCF-7) and Liver (HepG2) Cell Lines. Nanosci Nanotechnol Lett 2020; 12(3):324-30.
38. Jin Y, Zhu H, Zhu H, Jin F, Shi C, Yang L, Qian J, Zhang S. Fluorouracil Nanoliposomes Promote Apoptosis of Human Gastric Cancer Xenografts in Nude Mice. Nanosci. Nanotechnol. Lett 2020; 12: 690–695.
39. Zhang T, Su H, Xing Y, Zhang J, Xu D. Protective Mechanism of Lipid-Lowering Ketone and Self-Assembled OA Chitosan Nanoparticles on Insulin Oxidative Stress. Induced by High Fat in BRL-3A Cells. Nanosci. Nanotechnol. Lett 2020; 12: 715–719.
40. Zhang D, Lu Z, Sun B. Highly Sensitive Gold Nanoparticle Polymerase Chain Reaction in the Detection of Anaplastic Lymphoma Kinase-Positive Gastric Cancer from a Biopsy Specimen. Nanosci. Nanotechnol. Lett 2020; 12(4):498-505.
41. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Mod Genet J 2020; 15(2): 75-92.
42. Bai J, Guo T, Dong W, Song Y, Guo T, Cui M. Reduction of Breast Cancer Lymph Node Metastasis by Nano-Carbon Absorption of 5-Fluorouracil. Nanosci. Nanotechnol. Lett 2020; 12(3):407-12.